Firalis Molecular Precision

Proteomics solutions

Protein biomarker detection and quantification services and multiplexed immunoassay services powered by various cutting-edge technologies from Olink®, Quanterix®, and more

OUR TEAM

A powerful combination of scientific expertise and cutting-edge platforms allowing us to deliver customized proteomics solutions addressing the diverse and evolving needs of our clients.

OUR CAPABILITIES

Panel customization and validation, from protein biomarker discovery to validation | Multiplexed immunoassays | Automated immunoassay platform for biomarker detection | Ultra-sensitive protein biomarker detection system.

EXPLORE OUR SERVICES

Large scale protein identification Proteomics Services Olink Epmotion

Large-protein screening using Olink® technology

Firalis Molecular Precision positions itself as a certified Olink® Technology service provider and as one of the world’s first service providers.
Our experts leverage the Olink® Signature Q100 platform under GCLP conditions with the Flex and Target 48 panels. Target 96 and Explore panels are also leveraged for our services.

Our services play a pivotal role in drug target discovery, elucidating drug MoA, and conducting biomarker screening.

Absolute biomarker quantification with multiplexed immunoassays

With a repertoire of over +1000 validated assays, our immunoassay services feature cutting-edge technologies, including Bio-rad Luminex® BioPlex 200™, MSD Meso Sector S 600mm and Protein Simple ELLA™ for protein biomarker absolute quantification.

Specializing in cytokines testing, surrogate biomarkers, and biomarker validation, our services cater to diverse therapeutic areas, including immunology, oncology, cardiology, and neurology.

Immmunoassay protein detection Proteomics Services
Multiomics Solutions SIMOA Peoteomics Services Quanterix

Ultra-sensitive biomarker detection systems

Our experts leverage the Quanterix SR-X™, powered by the Simoa® bead technology, and Quanterix SP-X™ technologies.
These platforms, with applicability for immuno-oncology, neurological and inflammatory biomarkers, redefine protein detection and quantification, enabling researchers to explore ultra-low concentrations with sensitivity and precision.